European Primary Care Cardiovascular Society

ESC 2021

EPCCS reports on studies presented at the digital ESC 2021.

Continuous heart rhythm monitoring for the detection of AF

News - Oct. 5, 2021

ESC 2021 The LOOP study showed that continuous heart rhythm monitoring using an implantable loop recorder and initiation of OAC if AF was detected, did not prevent stroke in patients at high risk compared to standard care.

Quadruple combination pill to lower BP

News - Oct. 5, 2021

ESC 2021 The QUARTET trial showed that starting with a quarter-dose quadruple combination pill led to greater BP lowering compared to starting with standard dose monotherapy in patients with hypertension.

Lipid lowering therapy use in high and very high CV risk patients in Europe

News - Oct. 5, 2021

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.

Composite of death, MI or stent thrombosis reduced by flu vaccination after MI

News - Oct. 5, 2021

ESC 2021 The IAMI trial showed that influenza vaccination shortly after MI or in high risk CHD resulted in a reduced risk of the composite of all-cause death, MI or stent thrombosis at 12 months, compared to placebo.

Effective lowering of CV events by non-steroidal MRA in patients with diabetes and CKD

5' education - Oct. 5, 2021 - Prof. Bertram Pitt, MD
Prof. Pitt shares the results of the FIGARO-DKD trial. On top of optimized RAS blockade, the non-steroidal MRA finerenone significantly reduced the risk of the composite of time to CV death, non-fatal MI, non-fatal stroke or HF hospitalization.

ESC 2021 Prof. Pitt shares the results of the FIGARO-DKD trial. On top of optimized RAS blockade, the non-steroidal MRA finerenone significantly reduced the risk of the composite of time to CV death, non-fatal MI, non-fatal stroke or HF hospitalization.

Reduced CV outcomes with nonsteroidal MRA in patients with T2DM and mild-to-moderate CKD

News - Oct. 5, 2021

ESC 2021 The FIGARO-DKD trial showed that the nonsteroidal MRA finerenone significantly reduced the risk of CV outcomes in patients with mild-to-moderate kidney disease and diabetes.

A pooled analysis of two large HF trials with SGLT2i shows exciting findings

3' education - Oct. 5, 2021 - Milton Packer, MD
Data of two large trials with empagliflozin in patients with heart failure, EMPEROR-Reduced and EMPEROR-Preserved, were pooled for analysis. Milton Packer shares the findings of EMPEROR-Pooled.

ESC 2021 Data of two large trials with empagliflozin in patients with heart failure, EMPEROR-Reduced and EMPEROR-Preserved, were pooled for analysis. Milton Packer shares the findings of EMPEROR-Pooled.

2021 guidelines on CVD prevention recommend stepwise approach for prevention goals

News - Sep. 15, 2021

ESC 2021 The 2021 guidelines on CVD prevention in clinical practice contain recommendations at the individual and the population level. New at the individual level is a stepwise approach to intensify preventive treatments.

Benefit of SGLT2i in HFpEF by reduction of clinically meaningful CV events

3' education - Sep. 15, 2021 - Prof. Stefan Anker, MD, PhD
Prof. Anker talks about the rationale, design, results and implications of the EMPEROR-Preserved trial which investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin in patients with HFpEF.

ESC 2021 Prof. Anker talks about the rationale, design, results and implications of the EMPEROR-Preserved trial which investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin in patients with HFpEF.

A debate at ESC Congress: Benefit from omega-3 fatty acids?

News - Sep. 15, 2021
Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

Stroke reduction with replacement of salt by a salt substitute

News - Sep. 12, 2021
The Salt Substitute and Stroke Study (SSaSS) showed that replacement of salt (100% NaCl) with a salt substitute (75% NaCl + 25% KCl) reduces the risk of stroke in people with prior stroke or hypertension.

ESC 2021 The Salt Substitute and Stroke Study (SSaSS) showed that replacement of salt (100% NaCl) with a salt substitute (75% NaCl + 25% KCl) reduces the risk of stroke in people with prior stroke or hypertension.

Reduction of stroke, CV events and death when switching to a salt substitute

5' education - Sep. 12, 2021 - Prof. Bruce Neal, MD, PhD
Prof. Bruce Neal discusses the results of the SSaSS study which showed that replacing dietary salt with a salt substitute reduced stroke, CV events and death, without increasing the risk of hyperkalemia.

ESC 2021 Prof. Bruce Neal discusses the results of the SSaSS study which showed that replacing dietary salt with a salt substitute reduced stroke, CV events and death, without increasing the risk of hyperkalemia.

ESC 2021